NanoMed Pty Ltd is a nanobiotech company based in Sydney, Australia. NanoMed was founded in October 2016. Our technology is built upon over a decade of task-specific cutting-edge research conducted at CSIRO and a well-established core team of scientists with an excellent track record in translational science. Our mission is to design, develop and commercialise colloidal nanomedicines for use as cancer therapeutics and diagnostic imaging agents.
NanoMed’s core technology is focused on lipid-based nanomedicines. The key purpose is to expand and apply our patented technology which transforms cancer therapeutics currently in clinical use (e.g. 5-FU) into colloidal nanoparticles with efficacy gains beyond the reach of conventional methods.
Our nanomedicine platform overcomes the limitations of the conventional toxicity-efficacy trade off, by selectively targeting cancer cells, and keeping the prodrug inactive until taken up by cancer cells. The biophysical and biochemical constitution of our colloidal nanomedicines makes them ideal for combination (multi-drug and/or diagnostic agents) treatments and diagnostics with potential to improve prognoses for resistant cancers.
NanoMed has a mature network of clinical and scientific partners:
Kolling Institute at Royal North Shore Hospital (RNSH) and Sydney University
Brain and Mind Centre (BMC)
Australian Nuclear Science and Technology Organisation (ANSTO)
National Measurement Institute (NMI)
Australian National University (ANU)